- Conditions
- Amyotrophic Lateral Sclerosis, ALS
- Interventions
- Placebo, Ravulizumab
- Drug · Biological
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 382 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 34
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Loma Linda, California + 27 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 35
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Thrombotic Microangiopathy
- Interventions
- Ravulizumab, Best Supportive Care
- Drug · Other
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 8
- States / cities
- Tucson, Arizona • Aurora, Colorado • Atlanta, Georgia + 5 more
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria
- Interventions
- PNH-relevant therapies
- Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Interventions
- LNP023, Eculizumab, Ravulizumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 5
- States / cities
- Duarte, California • Orange, California • Augusta, Georgia + 2 more
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Interventions
- Ravulizumab, Eculizumab
- Biological
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Whittier, California • Fort Worth, Texas
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria, PNH
- Interventions
- Danicopan, Soliris/Ultomiris
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Dermatomyositis
- Interventions
- Ravulizumab, Placebo
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Irvine, California • Santa Monica, California + 17 more
- Conditions
- Preeclampsia
- Interventions
- Ravulizumab
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- IgAN, IgAVN, Immunoglobulin A Nephropathy, Immunoglobulin A Vasculitis Associated Nephritis, Henoch-schonlein Purpura Nephritis, IgA Vasculitis
- Interventions
- Ravulizumab
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 2
- States / cities
- Palo Alto, California • Aurora, Colorado
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Ravulizumab, Placebo
- Biological · Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Irvine, California • Loma Linda, California + 43 more
- Conditions
- Ultomiris-exposed Pregnant/ Postpartum, Pregnancy, Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS), Generalized Myasthenia Gravis (gMG), Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Interventions
- Ultomiris
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- Female only
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2034
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- COVID-19 Severe Pneumonia, Acute Lung Injury, Acute Respiratory Distress Syndrome, Pneumonia, Viral
- Interventions
- Ravulizumab, BSC
- Biological · Other
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 24
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Orange, California + 17 more
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria
- Interventions
- Cemdisiran, Eculizumab, Pozelimab, Ravulizumab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Whittier, California
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Interventions
- Ravulizumab, Eculizumab
- Biological
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 5
- States / cities
- Duarte, California • Los Angeles, California • Baltimore, Maryland + 2 more
- Conditions
- Neuromyelitis Optica
- Interventions
- Ravulizumab
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Atypical Hemolytic Uremic Syndrome (aHUS)
- Interventions
- Ravulizumab
- Biological
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 5
- States / cities
- Fort Wayne, Indiana • Durham, North Carolina • Winston-Salem, North Carolina + 1 more
- Conditions
- Atypical Hemolytic Uremic Syndrome (aHUS)
- Interventions
- Ravulizumab
- Biological
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 6
- States / cities
- Hollywood, Florida • Atlanta, Georgia • Detroit, Michigan + 3 more
- Conditions
- Chronic Kidney Disease, CKD, Cardiac Disease, Cardiopulmonary Bypass
- Interventions
- Placebo, Ravulizumab
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 555 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 16
- States / cities
- Orange, California • San Francisco, California • Stanford, California + 13 more
- Conditions
- Immunoglobulin A Nephropathy, IgAN
- Interventions
- Ravulizumab, Placebo
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 579 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 39
- States / cities
- Alabaster, Alabama • Phoenix, Arizona • Los Angeles, California + 30 more
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria
- Interventions
- Not listed
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 6,061 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- NMOSD
- Interventions
- Rituximab (R), Eculizumab (Soliris®), Ravulizumab, Satralizumab, Inebilizumab
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 540 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria
- Interventions
- Ravulizumab OBDS, Ravulizumab
- Combination Product · Biological
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 139 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
- Interventions
- Ravulizumab
- Biological
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 10
- States / cities
- Aurora, Colorado • Fort Collins, Colorado • Washington D.C., District of Columbia + 7 more
- Conditions
- Delayed Graft Function, DGF, Kidney Transplant
- Interventions
- Ravulizumab, Placebo
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Francisco, California + 26 more